Non-Restricted Immunoglobulin-G Subclass Islet Cell Antibodies in Chinese

References

• Irvine W J, Gray R S, McCallum C V. Pancreatic islet-cell antibody as a marker for asymptomatic and latent diabetes and prediabetes. Lancet 1976; II: 1097–102
   Google Scholar
• Gorsuch A N, Spencer K M, Lister J, McNally J M, Dean B M, Bottazzo G F, Cud worth A G. Evidence of a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 1981; II: 1363–65
   Google Scholar
• Groop L C, Bottazzo G F, Doniach D. Islet cell antibodies identify latent Type I diabetes in patients aged 35–75 years at diagnosis. Diabetes 1986; 35: 237–41
   PubMed Web of Science ®Google Scholar
• Johnston C, Millward B A, Hoskins P, Leslie R DG, Bottazzo G F, Pyke D A. Islet cell antibodies as predictors of the later development of Type I (insulin-dependent) diabetes. A study of identical twins. Diabetologia 1989; 32: 382–86
   PubMed Web of Science ®Google Scholar
• Bosi E, Becker F, Bonifacio E, Wagner R, Collins P, Gale E AM, Bottazzo G F. Progression to Type I diabetes in autoimmune endocrine patients with islet cell antibodies. Diabetes 1991; 40: 977–84
   PubMed Web of Science ®Google Scholar
• Niskanen L, Karjalainen J, Sarlund H, Siitonen O, Uusitupa M. Five-year follow-up of islet cell antibodies in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 402–8
   PubMedGoogle Scholar
• Kratzsch G, Rating T, Hedderich U. Classification of islet cell antibodies assessed by paraffin sections of human pancreas. Diabetologia 1981; 21: 294, Abstract
   Google Scholar
• Omar M AK, Srikanta S, Eisenbarth G S. Human islet cell antibodies: immunoglobulin class and subclass distribution defined by monoclonal antibodies. Diabetes Res 1987; 4: 155–57
   PubMedGoogle Scholar
• Millward A, Hussain M J, Peakman M, Pyke D A, Leslie D G, Vergani D. Characterization of islet cell antibody in insulin dependent diabetes: evidence for IgG1 subclass restriction and polyclonality. Clin. Exp. Immunol 1988; 71: 353–56
   PubMed Web of Science ®Google Scholar
• Schatz D A, Barrett D J, Maclaren N K, Riley W J. Polyclonal nature of islet cell antibodies in insulin-dependent diabetes. Autoimmunity 1988; 1: 45–50
   Google Scholar
• Nayak R C, Omar M AK, Rabizadeh A, Srikanta S, Eisenbarth G S. “Cytoplasmic” islet cell antibodies. Evidence that the target antigen is a sialoglycoconjugate. Diabetes 1985; 34: 617–19
   PubMed Web of Science ®Google Scholar
• Colman P G, Nayak R C, Campbell I L, Eisenbarth G S. Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipid. Diabetes 1988; 37: 645–52
   PubMed Web of Science ®Google Scholar
• Baekkeskov S, Aanstoot H-J, Christgau S, Reetz A, Solimena M, Cascalho M, Foili F, Richter-Olesen H, De Camilli P. Identification of the 64 K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 151–56
   PubMed Web of Science ®Google Scholar
• Thai A C, Ng W Y, Lui K F, Cheah J S (1993) Prevalence of islet-cell antibodies in Chinese patients with recent-onset insulin-dependent diabetes mellitus. International Diabetes Federation Western Pacific Region Congress, SeoulKorea, April, 121993, Abstract
   Google Scholar
• WHO Expert Committee on Diabetes Mellitus. World Health Organisation, Geneva 1985, Technical Report Series no 727
   Google Scholar
• Gleichmann H, Bottazzo G F. Immunology and Diabetes Workshop: report of the first international workshop on the standardization of cytoplasmic islet cell antibodies. Diabetologia 1986; 29: 125–26
   Google Scholar
• Jefferis R, Reimer C B, Skvaril F, De Lange G, Ling N R, Lowe J, Walker M R, Phillips D J, Aloisio C H, Wells T W, Vaerman J P, Magnusson C G, Kubagawa H, Cooper M, Vartdal F, Vandvik B, Haaijman J J, Makela O, Sarnesto A, Lando Z, Gergely J, Rajnavolgyi E, Laszlo G, Radl J, Molinaro G A. Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of an IUIS/WHO collaborative study. Immunol Letts 1985; 10: 223–52
   PubMed Web of Science ®Google Scholar
• Parkes A B, McLachlan S M, Bird P, Rees Smith B. The distribution of microsomal and thyroglobulin antibody activity among the IgG subclasses. Clin. Exp. Immunol 1984; 57: 239–43
   PubMed Web of Science ®Google Scholar
• Schauer R. Characterization of sialic acids. Complex Carbohydrates (Part C). Methods in Enzymology, V Ginsburg. Academic Press, New York San Francisco London 1978; Vol 50: 64–89
   Google Scholar
• Dean B M, Bottazzo G F, Cudworth A G. IgG subclass distribution in organ specific autoantibodies. The relationship to complement fixing ability. Clin Exp Immunol 1983; 52: 61–66
   PubMed Web of Science ®Google Scholar
• Bruining G J, Molenaar J, Tuk C W, Lindeman J, Bruining H A, Marner B. Clinical time-course and characteristics of islet cell cytoplasmatic antibodies in childhood diabetes. Diabetologia 1984; 26: 24–29
   PubMed Web of Science ®Google Scholar
• Bright G M. Quantitative assay for human cytoplasmic islet cell antibodies. Diabetes 1987; 36: 1183–86
   PubMed Web of Science ®Google Scholar
• Bright G M, Rust P F. Variability in islet cell antibody determination: A quantitative assessment. Autoimmunity 1989; 3: 281–87
   Web of Science ®Google Scholar
• Hoddinott S, Dornan J, Bear J C, Farid N R. Immunoglobulin levels, immunodeficiency and HLA in Type I (insulin-dependent) diabetes mellitus. Diabetologia 1982; 23: 326–29
   PubMed Web of Science ®Google Scholar
• Stromquist C, Berkel A I, Wilson D P, Gastorf J W, Nierenberg J. Serum immunoglobulin and IgG subclass levels in children and adolescents with insulin dependent diabetes mellitus. Acta Paediatr Scand 1989; 78: 639–40
   Google Scholar